TORONTO, IN / ACCESS CABLE / July 27, 2022 / NuGen Medical Devices Inc. (TSXV:NGMD)(OTCQB:NGMDF) (“NuGen” or the “Company”), a leader in needle-free drug delivery, is pleased to announce that, effective July 27, 2022, its common stock will begin to trade on the OTCQB under the symbol NGMDF. The company’s common shares will continue to trade on Canada’s TSX Venture Exchange under the symbol “NGMD”.
“Going public on the OTCQB Venture Exchange is an important milestone for NuGen,” said Michael Wright, CEO of NuGen. “Having our common shares available on the OTCQB will increase accessibility for US investors interested in participating directly in NuGen’s growth with the same ease as their Canadian counterparts.”
The OTCQB Venture Market for early-stage and developing US and international companies. The companies are up to date with their reports and undergo an annual management verification and certification process. Investors can find real-time quotes and market information for the company at www.otcmarkets.com.
The Company also advises that it is awaiting approval of its DTC eligibility application through the Depository Trust Company for electronic liquidation and transfer of its common shares in the United States.
About NuGen Medical Devices
NuGen is a specialty medical device startup developing the next generation of needle-free technologies and other innovative medical delivery products. The company’s products, including the InsuJet™ and PetJet™ needle-free injection systems, are designed to improve the lives of millions of people and animals. NuGen continues to receive approval in numerous countries, including Canada. NuGen products are designed for use in a number of important fields including, but not limited to, diabetes, veterinary medicine, and vaccines.
For more information contact:
president and CEO
NuGen Medical Devices Inc.
Investor Relations Contact:
kin communications inc.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking information that is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward-looking statements in this Press release They include the Company’s 2022 goals of securing additional sales and distribution agreements, filing for regulatory approvals and capitalizing on additional market opportunities. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained in this document is provided as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
FONT: NuGen Medical Devices
See source version at access cable.com: